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INTRODUCTION
Quantitative and qualitative immunologic reconstitution
following allogeneic bone marrow transplantation (BMT)
has been described, but the mechanisms by which lympho-
cytes recover and repopulate the immune system remain
unknown [1-7]. T-cells attain antigen speciﬁcity through a
process of receptor gene rearrangement guided through
positive and negative selection within the thymus. The cir-
culating pool of T-cells may be maintained through addition
of new/novel T-cells from the thymus or through expansion
(duplication) of existing mature cells. Mackall et al. com-
pared lymphocyte recovery in thymectomized versus thymus-
bearing mice following lethal irradiation and BMT [8].
Peripheral expansion was the dominant mechanism in
thymectomized animals but was suppressed and replaced by
central thymic production in the control mice. Following
transplantation from bone marrow or peripheral blood stem
cells in adult humans, early T-cell reconstitution favors cells
with the memory phenotype, then shifts to roughly equal
parts memory and naïve phenotypes [6].
Until recently, no techniques were available to measure
thymic production of new T-cells. Recent thymic emigrants
(naïve T-cells) have been described phenotypically as
expressing both CD45RA and L-selectin (CD62L). Following
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ABSTRACT
T-cell recovery following myeloablative preparatory regimens and cord blood transplantation in adult patients gen-
erally occurs between 1 and 3 years following allogeneic bone marrow transplantation. T-cell reconstitution may
involve thymic education of donor-derived precursors or peripheral expansion of mature T-cells transferred in the
graft. We measured quantitative and qualitative immunologic reconstitution, T-cell receptor spectratyping, and T-cell
receptor excision circle (TREC) levels in adult recipients of umbilical cord blood transplants following a novel non-
myeloablative regimen. These results were compared to previously published results of similar patients receiving a
myeloablative regimen and cord blood stem cells. With small numbers of patients treated so far, T-cells (CD3+)
reached normal levels in adults 6 to 12 months following nonmyeloablative transplantation compared with 24 months
in adults receiving a myeloablative regimen. At 12 months after transplantation, the numbers of phenotypically
naïve (CD45RA+) T-cells were higher in those receiving the nonmyeloablative regimen. The T-cell repertoire in
cord blood recipients treated with a nonmyeloablative regimen was markedly more diverse and robust compared
with the repertoire in those receiving the myeloablative regimen at similar time points. TRECs (which are gener-
ated within the thymus and identify new thymic emigrants and those that have not divided) were detected 12 months
after transplantation in the nonmyeloablative recipients, whereas TRECs were not detected in adults until 18 to
24 months in those receiving myeloablative regimens. Thus, in adults receiving a nonmyeloablative preparatory reg-
imen, the quantitative and qualitative recovery of T-cells occurs through rapid peripheral expansion. The ability of
patients receiving a nonmyeloablative regimen to recover within a few months suggests that the peripheral niches in
which T-cells can proliferate are preserved in these patients compared to those receiving ablative regimens. More-
over, the presence of TREC-positive cells within 1 year suggests that thymic recovery is likewise accelerated in non-
myeloablative compared to myeloablative regimens.
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contact with its speciﬁc antigen, the T-cell is activated and
may become a memory T-cell identiﬁed phenotypically by
expression of CD45RO. Unfortunately, phenotypic markers
are not reliable because naïve T-cells can expand extrathymi-
cally without stimulation [9], and memory cells may (sponta-
neously) revert back to the naïve phenotype [10].
A novel method to measure thymic production has been
described [11]. T-cell precursors expressing the Vβ T-cell
receptors (TCR) attain antigen specificity in the thymus.
Their development requires rearrangement of the TCR
genes occupying 3 loci. Rearrangement of the TCRA locus
brings together a random selection of single gene segments
from 2 variable segment families, V and J, and the constant
segment C. Intervening segments are excised in predictable
steps and form circular episomes as a by-product. Two of
these recombination steps are identical in a majority of
TCRA locus rearrangements and result in 2 circular epi-
somes: the signal-joint TCR excision circle (sjTREC) and
the coding-joint TREC [11]. A polymerase chain reaction
(PCR)-based assay has been developed [12] to measure the
amount of sjTREC DNA contained in a population of T-cells.
As T-cells proliferate, they replicate the recombined TCR
genes but not the episomal sjTRECs. An increasing concen-
tration of sjTREC DNA in the peripheral blood of trans-
plant recipients indicates maturation of new T-cells from
the progenitor pool and subsequent potential for diversiﬁca-
tion of the T-cell repertoire.
Recently, several groups have measured sjTREC-con-
taining T-cells following allogeneic transplantation [13-16].
In our previous study, immunologic reconstitution was ana-
lyzed following unrelated umbilical cord blood (UCB) trans-
plantation in adults and children to determine the source of
the regenerated T-cell pool. UCB is phenotypically naïve but
T-cell replete, allowing for T-cell reconstitution through
either central or peripheral mechanisms. Reconstitution of
immunity following UCB transplantation occurred over a
period of 2 to 3 years for both adult and pediatric recipients.
Both patient groups eventually demonstrated a normal lym-
phocyte count with a quantitatively normal distribution of
B-cells, T-cells, and natural killer (NK) cells. The sources of
T-cells, however, appear strikingly different. Pediatric recipi-
ents demonstrated signiﬁcant numbers of sjTREC-containing
T-cells starting within 1 year after transplantation, indicating
that the T-cells are recent thymic emigrants. In contrast,
adult recipients failed to demonstrate any sjTREC-containing
T-cells until 11⁄2 to 2 years after transplantation, and then
only at relatively low levels. These results suggest that adult
recipients of cord blood had a very slow recovery of T-cell
numbers and function.
Recently, less toxic nonmyeloablative regimens using
peripheral blood stem cells or marrow from matched donors
have allowed the expansion of allogeneic stem cell trans-
plantation to older, more debilitated patients [17,18]. This
approach is still limited by the lack of matched sibling
donors, and alternative donor sources must be sought. We
have been investigating the feasibility of using cord blood as
the stem cell source [19]. This report describes the recovery
of T-cells in 5 recipients of cord blood transplants following
a nonmyeloablative regimen compared to recovery in adult
recipients of cord blood following a myeloablative regimen.
METHODS
Patients
Patient characteristics are summarized in Table 1. Five
adult patients without a suitable HLA-matched related or
unrelated bone marrow donor underwent mismatched unre-
lated cord blood transplantation between May 2000 and
May 2001 at Duke University Medical Center (DUMC).
The diagnoses included refractory mantle cell lymphoma,
refractory diffuse large cell lymphoma (after failing autolo-
gous stem cell transplantation), renal cell carcinoma,
myelodysplastic syndrome, and refractory γ-δ T-cell lym-
phoma. None of these patients had prior radiation to a
mantle ﬁeld (affecting the thymus). All patients were treated
following a phase I protocol approved by the DUMC Insti-
tutional Review Board. Informed consent was obtained from
all patients. Adult patients receiving a myeloablative
preparatory regimen and cord blood transplantation have
been previously described [16]. The clinical aspects of the
ﬁrst 2 recipients of the nonmyeloablative regimen have also
been reported [19].
Conditioning
Conditioning included the use of ﬂudarabine 30 mg/m2
and cyclophosphamide 500 mg/m2 daily for 4 days (days –5
to –2) with antithymocyte globulin (ATG) 30 mg/kg per day
for 3 days (days –3 to –1). Mismatched unrelated cord blood
was infused on day 0. All the grafts were 4/6 HLA matches.
Graft-versus-Host Prophylaxis
All patients received cyclosporine (CYA) and methyl-
prednisolone for graft-versus-host disease (GVHD) prophy-
laxis. Patients received CYA with an intermediate dose of
Table 1. Patient Characteristics*
UPIN #2379 UPIN #2593 UPIN #2601 UPIN #2611 UPIN #2679
Time WBC Plt % Donor WBC Plt % Donor WBC Plt % Donor WBC Plt % Donor WBC Plt % Donor
2 wk 3.5 29† 6.5 0.2 19† 93 5.8 105 1 0.2 9† 37 7.3 387 0
6 wk 1.3 19† 18 7.7 8† 100 6.5 205 0 10.2 19† 8 5.5 135 0
8 wk 7.9 31 56 4.3 8† 100 3.5 224 0 4.3 13† 4
3 mo 4.7 92 100 5.4 36 100 4.6 132 10
6 mo 6.2 123 100 9.1 111 100 7.8 123 100
12 mo 5.4 154 100 7.8 132 100
*Plt indicates platelet count; % donor, lymphoid donor chimerism determined by microsatellite polymorphisms.
†Transfused value.
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methylprednisolone (1 mg/kg per day on days 0 through +4,
3 mg/kg per day on days +5 through +13, 2 mg/kg per day
on day +14 through day +27, followed by a daily dose tapered
by 10% each week). Methylprednisolone was changed to oral
prednisone when the patient was able to tolerate oral intake.
The dosages of CYA were adjusted to maintain serum levels
between 200 and 400 ng/dL. Patients were scored for
GVHD according to established criteria [20]. CYA and pred-
nisone were tapered over several months starting at day +180
in those patients without evidence of chronic GVHD.
Immunologic Recovery
Immune recovery was analyzed with quantitative and
qualitative measures at least every 3 months for the ﬁrst year
after transplantation. Peripheral blood was analyzed
through the hospital clinical laboratory to measure the total
white blood cell count (WBC) and absolute lymphocyte
count (based on an automated or manually interpreted
blood smear). Lymphocyte subsets (B, T, memory versus
naïve T, and NK) were enumerated using multiparameter
flow cytometry. Peripheral blood mononuclear cells
(PBMC) were prepared by Ficoll separation of freshly
drawn heparinized whole blood followed by staining with
fluorescent-labeled monoclonal antibodies. Samples were
stained with a standard panel of antibodies, including anti-
CD2, CD3, CD4, CD8, CD16, CD19, CD20, CD10, and
CD45, CD56, TCRαβ, TCRγδ, CD45RA, and CD45RO.
FastImmune analysis (CD69, Becton Dickinson, San Jose,
CA) expression was also monitored. Analysis was performed
on a FACSCalibur ﬂow cytometer (Becton Dickinson).
TREC Measurement
The concentration of sjTREC DNA in PBMC was
measured by quantitative competitive (QC)-PCR following
a method previously described [15]. Brieﬂy, DNA was iso-
lated from 5 × 104 CD3+ using the Life Technologies TRI-
ZOL Reagent protocol (Gaithersburg, MD) or proteinase K
digestion. DNA was resuspended in 100 µL of 8mM
NaOH; the resulting concentration of DNA was deter-
mined by spectrophotometry. DNA (1 µg) was ampliﬁed for
30 cycles using a 60°C annealing temperature and extension
at 72°C for 30 seconds in a 50-µL PCR reaction mix con-
taining: 1× PCR buffer (Platinum Taq, Life Technologies)
2.5 µL, 50-mM MgCl2 1.75 µL, 10-µM deoxynucleoside
triphosphate (dNTP) 0.5 µL, 12.5-µM sjTREC Primer A
1 µL, 12.5-µM sjTREC B 1 µL, 2.5 µCi 32P deoxycytidine
triphosphate (dCTP), 0.125 µL Platinum Taq Polymerase
(Life Technologies), and either 5000, 1000, 500, or 100 mol-
ecules of sjTREC standard (60 base pairs shorter than the
target sjTREC sequence). PCR products were separated on
6% or 8% polyacrylamide gels. The gels were dried and
bands visualized on a PhosphorImager screen (Molecular
Dynamics, Sunnyvale, CA) and quantified using Image-
Quant software. In this assay, the limit of detection was
>100 sjTRECs/µg DNA.
CDR3 Spectratyping
CDR3 spectratyping (immunoscope) was performed
every 3 months. Immunoscope analysis involves preparing
cDNA and performing 23 PCR reactions using a common
C-region primer and separate V-region–specific primers,
followed by primer extension and PCR amplification with
1 of 12 separate J-region–speciﬁc labeled primers as previ-
ously described [21-23]. The product is then sequenced with
a DNA sequencer (Applied Biosystems, Foster City, CA).
Size determination of the run-off products is performed
automatically. The different peaks are separated, and their
CDR3 size in amino acids is calculated for each Vβ gene
family. Histogram peaks were defined by the Genotyper
Genescan software analysis program (Applied Biosystems).
Further analysis was performed by magnetic selection of the
CD3+ cells into CD4+ and CD8+ cells and then performance
of the immunoscope analysis.
RESULTS
Clinical Recovery
Four of the 5 patients had clear evidence of donor cells.
One patient never had any evidence of detectable donor cells.
Another patient had minimal (1%) transient detectable donor
cells, but these cells did not persist. The other 3 patients had
full donor chimerism established between 6 weeks and
6 months following the nonmyeloablative cord blood trans-
plantation (Table 1).
Acute GVHD did not occur except in 1 patient (UPN
2611) who developed grade II GVHD and subsequently
died of disseminated Aspergillus flavus infection. No other
patients experienced any unusual or unexpected toxicities.
As of this report, relapse of the underlying disease had not
occurred in the patients with engraftment.
Lymphocyte Subsets
Lymphocyte subset analysis and proliferation assays were
performed on all patients who had engraftment. We previ-
ously reported that the absolute lymphocyte count remained
below normal until the 2-year follow-up [16]. In contrast, the
patients who achieved engraftment had a rapid recovery to
normal levels within 6 months, at which time all the cells in
the peripheral blood were of donor origin according to
microsatellite polymorphism analysis. Naïve (CD45RA+,
CD62L+) and memory (CD45RO+, CD62L–) T-cell popula-
tions were likewise quite different (Table 2). The recovery of
naïve cells for 1 patient (UPN2593) throughout the first
6 months is demonstrated in Figure 1.
Immunoscope
Five randomly chosen cord blood units that were not
used clinically were tested for their T-cell repertoire. The
median number of peaks identiﬁed in each of the UCB grafts
was 141 (range, 121-185), consistent with previously pub-
lished data [21]. Spectratyping from the 3 nonmyeloablative
Table 2. Lymphocyte Recovery
Median Lymphocyte Median CD45RA Median CD45RO
Time Count (Range) (Range) (Range)
3 mo 355 (225-448) 263 (182-345) 182 (180-185)
6 mo* 2050 (87-3264) 987 (113-1860) 608 (110-1106)
1 y* 4135 (1962-6308) 2477 (980-3974) 1234 (765-1703)
*At 6 months and forward, all cells were of donor origin (total of
3 patients with engraftment).
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recipients demonstrated a remarkable recovery of complexity
as early as 3 months following the nonmyeloablative regimen.
In contrast, recipients of the ablative regimen demonstrated
repertoire skewing between 1 and 2 years after transplanta-
tion: the overall number of Vβ families represented and the
number of peaks within each family were limited. T-cell
repertoires appeared to be more diverse when tested 3 years
after transplantation, but they remained substantially skewed
in 1 patient. Fluorescence intensity spectra for each of 23 Vβ
families obtained from 2 of the nonmyeloablative recipients
are presented in Figure 2. As early as 6 months after trans-
plantation, at a time when all the engrafted patients had full
donor chimerism, the repertoire appeared complex. In con-
trast, Figure 3 shows results from a typical adult patient fol-
lowing an ablative preparatory regimen sampled 1 year after
UCB transplantation compared to those from a patient
receiving a nonmyeloablative regimen at 6 months. The con-
trast between the 2 immunoscopes is striking.
To further understand the contribution of the CD4 and
CD8 cells to the complexity of the T-cell repertoire, CD3+
cells were further selected into CD4+ and CD8+ cells using
magnetic beads (Miltenyi, Auburn, CA). Figure 4 shows one
representative example of a patient 1 year following a non-
myeloablative regimen. The data suggest not only that the
naïve cells are recovering faster but that there is a bias
toward increased complexity in the CD4+ cells compared to
the CD8+ cells.
sjTREC Assay
QC-PCR for sjTREC DNA was performed on samples of
peripheral blood. TRECs were not detectable prior to 1 year
(at 3, 6, and 9 months). By the 1-year mark, both of the surviv-
ing patients had sjTRECs above the detection threshold in the
peripheral blood (>100 sjTRECs/µg PBMC DNA) with val-
ues of 120 and 157 TRECs/µg PBMC DNA. Five randomly
chosen cord blood units (not used in any of the patients pre-
sented) were also sampled for sjTRECs, and their median was
3913 copies/µg PBMC DNA (standard error, 2291).
DISCUSSION
This report compares quantitative and qualitative
immunological recovery following an unrelated partially
matched UCB transplantation in patients receiving a non-
myeloablative or a myeloablative preparatory regimen. Stud-
ies of immune recovery after matched-sibling allogeneic
transplantation have demonstrated quantitative recovery of
T-cells at between 6 and 12 months after transplantation.
After an ablative regimen and UCB transplantation in 18 adult
patients, the T-cell numbers did not reach the lower limit of
Figure 1. Fluorescence-activated cell sorting (FACS) analysis of 1 patient’s recovery of naïve phenotype T-cells over the course of 6 months follow-
ing a nonmyeloablative unrelated mismatched cord blood transplantation. FITC indicates ﬂuorescein isothiocyanate; APC, allophycocyanin; PE,
phycoerythrin.
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normal until the second year [16]. Memory T-cells were the
dominant subpopulation for the ﬁrst year after transplanta-
tion in adults. The contribution of naïve T-cells increased in
the second and third years to equal that of memory cells,
coinciding with the appearance of a low level of sjTREC-
containing T-cells and improvement in proliferative
responses. Reconstitution of T-cells, although it was mar-
ginal, occurred principally through peripheral expansion for
at least the first 18 months after transplantation. Thymic
production of new T-cells contributed to the T-cell pool 2 or
more years after transplantation.
In contrast, the rate of T-cell recovery was markedly dif-
ferent for recipients of UCB transplants who were prepared
with a nonmyeloablative regimen. In these patients, the
preparatory regimen was the primary difference between the
2 patient populations. The GVHD prophylaxis, ATG dose,
and supportive care were identical. The only other major
difference was that the patient population receiving the
nonmyeloablative regimen had more advanced disease or
had a poorer performance status that made them ineligible
for conventional ablative UCB transplantation. Although
memory T-cells were the dominant subpopulation for the
patients receiving the ablative regimen, a rapidly expanding
naïve population outnumbered the memory cells in the
recipients of the nonmyeloablative regimen. These results
are similar to the rapid recovery of naïve CD4+ cells seen in
children following nonmyeloablative chemotherapy [24].
The naïve cells brought the total T-cell count up into the
normal range by 1 year after transplantation. In contrast to
those receiving the ablative regimens, 2 patients that
received nonmyeloablative transplantations had detectable
sjTRECs in as early as 1 year after transplantation. The
third patient who also engrafted developed acute GVHD,
and her recovery was not as robust. The rapid rise of naïve
cells and the detectable levels of sjTRECs show that in the
recipients of nonmyeloablative regimens, the thymus is
functional early in the posttransplantation course, maturing
bone marrow–derived precursor T-cells. Although cord
blood itself does contain substantial numbers of new thymic
emigrants, sjTRECs remain undetectable through the ﬁrst
year after transplantation. The later increase, therefore, can-
not be attributed to adoptive transfer of sjTRECs in the
graft but must come from new thymic function. Lastly,
although the measured parameters point to a recovering
immune system, functional studies are also important. Mito-
gen responses in the 2 patients with good engraftment have
been very robust and not different from those of healthy
controls (data not shown). Measurements for cytomegalo-
virus (CMV) responses using CMV antigen and the FAS-
TImmune assay (CD69 measurement) at the 1-year mark
have not yet demonstrated sufﬁcient responses to convinc-
ingly demonstrate a robust CMV response. However, CMV
Figure 2. Composite spectratyping of 2 patients’ recovery over the ﬁrst year following a nonmyeloablative unrelated mismatched cord blood trans-
plantation. Note the gradual increase in the complexity of the TCR families.
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reactivation has not been observed in the 3 patients that
have had engraftment. Further functional studies are neces-
sary in these patients.
UCB has proven to be a valuable source of hematopoietic
progenitor cells for transplantation into pediatric and adult
patients for whom a matched-related donor is not available.
Advantages over HLA-matched unrelated donor sources
include rapid graft availability and relative insensitivity to
HLA disparity manifested as a low incidence of GVHD [1].
At the same time, adult UCB transplant recipients are at
increased risk for opportunistic infections for at least 2 to
3 years after transplantation. Infection may account for half of
all treatment-related deaths after UCB transplantation fol-
lowing an ablative regimen [2]. This risk for infection may be
an intrinsic property of cord blood, because UCB T-cells
have been shown to be phenotypically naïve [21] and to
expand slowly in response to antigen stimulation, demon-
strate a higher threshold for cytokine stimulation, and possess
a lower effective cytotoxicity relative to adult donor T-cell
controls [25,26]. Moreover, thymic production of new T-cells
is substantially delayed and remains limited in adult recipients
of UCB following an ablative preparatory regimen.
In our previous comparison between adult and pediatric
recipients of UCB transplant, the disparity between adult
and pediatric patients suggested that host-speciﬁc or post-
transplantation factors are at work: thymic atrophy due to
age, GVHD, immunosuppressive drug effect, or other as-yet-
undetermined age-related factors. Thymic function declines
with age [27-29]. The thymus of adult recipients may have
naturally atrophied and/or been exposed to more chemo-
therapy (or environmental toxin) prior to BMT than that of
pediatric recipients, resulting in a delayed response. In fact,
the measured TREC levels in adults were lower than
expected for median age as predicted for healthy controls.
However, peak thymic function may not yet have been
reached in the adult UCB recipients. If the reconstituted
T-cell pool after transplantation is derived solely by expansion
of the adoptively transferred “mature” cord blood cells, the
repertoire of antigen speciﬁcities may be severely limited.
Yet, the conclusions from our previous ﬁndings with the
myeloablative preparatory regimen are challenged by the
ﬁndings of immune recovery following the nonmyeloablative
regimen. In a similar patient population (all adults), using
identical supportive care and GVHD prophylaxis, the current
study demonstrates that unrelated mismatched UCB can pro-
liferate in the periphery quite nicely, giving rise to mature
T-cells with remarkably robust complexity. These results sug-
gest that the donor cells only need a niche in which they can
proliferate and that the nonmyeloablative regimen does not
destroy these niches. Moreover, although the peripheral
Figure 3. Fluorescence intensity spectra for each of the 23 Vβ families (and 1 positive control) from a representative recipient of an unrelated mis-
matched cord blood transplant following an ablative regimen (left) at 1 year compared to a recipient of a nonmyeloablative unrelated mismatched
cord blood transplantation (right) at 6 months following transplantation.
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mechanisms of T-cell expansion are preserved, there is also a
suggestion that the central mechanism (thymus) is likewise
preserved, in that TREC-positive cells can be detected as
early as 1 year following transplantation. Similar results have
been reported by Friedman et al. In that report, the authors
demonstrated that the patients who received the nonmye-
loablative conditioning and either bone marrow or peripheral
blood matched unrelated stem cells exhibited more rapid
reconstitution of T-cell repertoire complexity [30]. These
authors clearly demonstrated the spectratyping differences
based on the type of conditioning regimen.
Although the risk of GVHD following cord blood trans-
plantation is lower than that following matched sibling allo-
geneic bone marrow or stem cell transplantation, GVHD
does occur. GVHD has been shown to affect thymic tissue
and may render the thymus unable to generate new T-cells.
Alternatively, medical prophylaxis to prevent GVHD
(cyclosporin or FK506) may injure the thymus and/or pre-
cursor T-cells. Acute GVHD did not occur in the 2 patients
studied in the most detail, and the presence of sjTRECs
might be a reflection of a lack of thymic injury from
GVHD. This lack of injury would not be surprising given
that the incidence of acute GVHD may be lower in recipi-
ents of nonmyeloablative regimens.
Although not apparent in this analysis, the potential for
“holes” in the T-cell repertoire may exist in adult patients.
These holes could result from transplantation of a limited
number of mature donor T-cells or a subsequent toxic insult
to the grafted T-cells (including GVHD prophylaxis). Such
voids would be permanent without thymic maturation of
new precursor T-cells with novel TCR gene rearrange-
ments. Moreover, the delay in TREC-positive T-cells may
also have important implications in the timing of immuniza-
tion and posttransplantation immunotherapy [26]. The
results of T-cell recovery following the nonmyeloablative
regimen suggest that it may be possible to have an excellent
outcome with an unrelated mismatched cord blood trans-
plant in adult patients. Patients have a rapid recovery of
myeloid cells and platelets and a rapid recovery of T-cells
with a complex diversity. The primary difference between
the recipients of ablative and nonablative regimens was the
extent of physiologic damage caused by the preparatory reg-
imen. When the damage is relatively mild, the donor T-cells
are able to expand effectively in the periphery, and the
development of new T-cells through the thymus is also
accelerated compared to the rate of development in those
receiving ablative regimens. Alternatively, the lower inci-
dence of acute GVHD may also play an important role in
the preservation of the peripheral and central niches for
T-cell development. Future investigation will focus on
increasing the chances of engraftment following this non-
myeloablative regimen and expanding these observations.
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